[
    {
        "file_name": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement.txt",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "4.1.2 Number of Sales Representatives. Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.",
                "changed_text": "4.1.2 Number of Sales Representatives. Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant should aim to maintain around one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.",
                "explanation": "The change replaces \"Valeant shall maintain at least one hundred (100) Sales Representatives\" with \"Valeant should aim to maintain around one hundred (100) Sales Representatives\". This change weakens the obligation to a suggestion, creating uncertainty about whether maintaining a specific number of sales representatives is mandatory or discretionary.",
                "location": "Section 4.1.2"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "4.4.1 Training, Training Materials and Promotional Materials.\n\n(a) Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content of (i) all Product training materials for Field Force Personnel (the \"Product Training Materials\") and (ii) all Product marketing and educational materials (the \"Promotional Materials\") (the Product Training Materials and the Promotional Materials, collectively, the \"Product Materials\"). Dova shall be solely responsible for ensuring that the Product Materials prepared and approved by it are in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova, the content of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of such Product Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions to such Product Materials, which comments and revisions Dova shall reasonably consider so long as Dova deems such suggestions are acceptable in the promotion of the Product; provided that in any event, to the extent that Dova reasonably believes that such changes are not in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova shall not be required to incorporate any such suggestions from Valeant in the Product Materials. In the event of any disagreement between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova shall have the right to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova accepts some or all of such comments, then, once revised, Dova shall provide to Valeant the revised versions of such Product Materials for further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant shall use only Product Materials approved by Dova in the performance of Valeant Activities under this Agreement; provided, however, that Valeant shall not be required to use any Product Materials that have not been approved by Valeant or which have not incorporated comments provided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant reserves the right not to use certain Product Materials. The content of Product Materials shall not be modified or changed by Valeant or Field Force Personnel at any time without the prior written approval of Dova in each instance. Dova shall be responsible for the costs and expenses of creation and development of the Product Materials and Valeant shall be responsible for the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties will coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova incurs costs and expenses for which Valeant is responsible under this Section 4.4.1, Dova may deduct such amounts from the payments due under Section 6.3 and shall include a description thereof in the applicable report under Section 6.3. Promptly after the Effective Date, the Parties will collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as reasonably practical.",
                "changed_text": "4.4.1 Training, Training Materials and Promotional Materials.\n\n(a) Subject to the terms of this Section 4.4.1, Dova should strive to prepare and control the content of (i) all Product training materials for Field Force Personnel (the \"Product Training Materials\") and (ii) all Product marketing and educational materials (the \"Promotional Materials\") (the Product Training Materials and the Promotional Materials, collectively, the \"Product Materials\"). Dova will endeavor to be solely responsible for ensuring that the Product Materials prepared and approved by it are in compliance with the Regulatory Approval for the Product, the Product Labeling and Applicable Law. Once approved by Dova, the content of the Product Materials will possibly be provided by Dova to Valeant in advance of the Valeant Activates to allow for Valeant to review such content and provide verbal feedback to Dova in advance of use of the Product Materials. Within [***] of receipt of such Product Materials, Valeant will perhaps verbally provide to Dova any comments and/or proposed revisions to such Product Materials, which comments and revisions Dova might reasonably consider so long as Dova subjectively views such suggestions as acceptable in the promotion of the Product; provided that in any event, to the extent that Dova arguably believes that such changes are not in compliance with Applicable Law, the Regulatory Approval for the Product or the applicable Product Labeling, then Dova may not be required to incorporate any such suggestions from Valeant in the Product Materials. In the hypothetical event of any disagreement between the Parties regarding any feedback received from Valeant with respect to the Product Materials, Dova has the option to conclusively determine such matter. If Valeant has provided comments to Dova on the Product Materials and Dova happens to accepts some or all of such comments, then, once revised, Dova will aim to provide to Valeant the revised versions of such Product Materials for further review by Valeant, in accordance with the terms and timelines of this Section 4.4.1(a) above. Valeant might use only Product Materials approved by Dova in the performance of Valeant Activities under this Agreement; provided, however, that Valeant must use any Product Materials, even those that have not been approved by Valeant or which have not incorporated comments provided by Valeant and nothing herein shall require Valeant to use all Product Materials created or prepared by Dova and Valeant reserves the right not to use certain Product Materials. The content of Product Materials must not be modified or changed by Valeant or Field Force Personnel at any time without the prior reasonable approval of Dova in each instance. Dova assumes reasonable responsibility for the costs and expenses of creation and development of the Product Materials and Valeant is charged with reasonable responsibility for the costs and expense of reproduction, printing and delivery of the Product Materials to and for Valeant. The Parties may coordinate the production and delivery of Product Materials to allow sufficient internal and field force review time to accommodate scheduled training meetings and distribution to Field Force Personnel that are engaged in Detailing. In the event that Dova bears costs and expenses for which Valeant is plausibly responsible under this Section 4.4.1, Dova may deduct such amounts from the payments due under Section 6.3 and might include a description thereof in the applicable report under Section 6.3. Possibly after the Effective Date, the Parties will plan to finalize the Product Materials in accordance with this Section 4.4.1(a), as soon as reasonably practical.",
                "explanation": "This modification inserts vague and discretionary language throughout Section 4.4.1(a), which concerns the preparation, control, and use of Product Materials. For example, \"Dova shall prepare and control\" becomes \"Dova should strive to prepare and control\", and \"Dova shall be solely responsible\" becomes \"Dova will endeavor to be solely responsible\". The insertion of words like \"might\", \"possibly\", \"perhaps\", and \"hypothetical\" weakens the obligations on both parties, creating ambiguity as to whether they must perform these actions, undermining the clarity and enforceability of the agreement.",
                "location": "Section 4.4.1(a)"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "10.2 Representations and Warranties of Valeant. Valeant represents and warrants to Dova as of the Effective Date that:\n\n10.2.1 it is a limited liability company duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;\n\n10.2.2 the execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action;\n\n10.2.3 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;\n\n10.2.4 this Agreement constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\n\n10.2.5 the execution, delivery and performance of this Agreement by Valeant does not require the consent of any Person or the authorization of (by notice or otherwise) any Governmental Authority or the FDA;\n\n10.2.6 there is no action, suit or proceeding pending or, to the knowledge of Valeant, threatened, against Valeant or any of its Affiliates, or to the knowledge of Valeant, any Third Party acting on their behalf, which would be reasonably expected to impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits of this Agreement;\n\n10.2.7 it is in compliance in all material respects with all Applicable Laws applicable to the subject matter of this Agreement;\n\n10.2.8 it has the right to market and sell the Designated Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to make, use, sell and offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals are in good standing;\n\n10.2.9 it is not a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way limits or conflicts with its ability to execute and deliver this Agreement and to fulfill any of its obligations under this Agreement;\n\n10.2.10 it has no knowledge of any information relating to any communications with any Governmental Authority, which would reasonably be expected to materially impair, restrict, prohibit or affect Valeant's ability to perform its obligations and enjoy the benefits of this Agreement;\n\n10.2.11 neither Valeant nor any of its personnel (i) have been debarred under the 21 U.S.C. ยง 335a, (ii) are excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Valeant or any of its personnel become or are the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C. ยง 335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Valeant shall immediately notify Dova, and Dova shall have the option to prohibit such Person from performing work under this Agreement; and\n\n10.2.12 all Field Force Personnel that are engaged in Detailing are, and will be, licensed to the extent required and in accordance with all Applicable Laws.",
                "changed_text": "10.2 Representations and Considerations of Valeant. Valeant will consider to Dova as of the Effective Date that:\n\n10.2.1 it might be a limited liability company organized and existing under the laws of the state or other jurisdiction of its incorporation;\n\n10.2.2 the execution, delivery and performance of this Agreement by it should be authorized by all requisite corporate action;\n\n10.2.3 it may have the power and authority to execute and deliver this Agreement and to strive to perform its obligations hereunder;\n\n10.2.4 this Agreement arguably constitutes a legal, valid and plausibly binding obligation against it in accordance with its terms, and the enforcement may be considered subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);\n\n10.2.5 the execution, delivery and performance of this Agreement by Valeant might not require the consent of any Person or the authorization of (by notice or otherwise) any Governmental Authority or the FDA;\n\n10.2.6 potentially there is no action, suit or proceeding pending or, to the knowledge of Valeant, threatened, against Valeant or any of its Affiliates, or to the knowledge of Valeant, any Third Party acting on their behalf, which could possibly impair, restrict or prohibit the ability of Dova or Valeant to perform its obligations and attempt to enjoy the benefits of this Agreement;\n\n10.2.7 it will strive to comply in all material respects with all Applicable Laws applicable to the subject matter of this Agreement;\n\n10.2.8 it potentially has the right to market and sell the Designated Product in the Territory as contemplated herein and has all licenses, authorizations, permissions, consents or approvals from any applicable Governmental Authority including the FDA necessary to attempt to make, use, sell and attempt to offer to sell the Product in the Territory and all such licenses, authorizations, permissions, consents or approvals must plausibly be in good standing;\n\n10.2.9 it might not be a party to any agreement or arrangement with any Third Party or under any obligation or restriction agreement (including any outstanding order, judgment or decree of any court or administrative agency) which in any way might limit or conflict with its ability to execute and deliver this Agreement and to aim to fulfill any of its obligations under this Agreement;\n\n10.2.10 it has nearly zero knowledge of any information relating to any communications with any Governmental Authority, which arguably would materially impair, restrict, prohibit or affect Valeant's ability to perform its obligations and relish the benefits of this Agreement;\n\n10.2.11 probably neither Valeant nor any of its personnel (i) have been debarred under the 21 U.S.C. ยง 335a, (ii) are excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) are convicted of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal health care programs but has not yet been excluded, debarred, suspended, or otherwise declared ineligible to participate in those programs, (iv) are listed on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) are listed on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov). If, during the Term, Valeant or any of its personnel become or are the subject of a proceeding that could lead to, as applicable, (i) debarment under 21 U.S.C. ยง 335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration's List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Valeant shall strive to notify Dova, and Dova will regard having the possibility to prohibit such Person from performing work under this Agreement; and\n\n10.2.12 most Field Force Personnel that are engaged in Detailing are, and could be, licensed as the case may be based on requirements and in accordance with all Applicable Laws.",
                "explanation": "By replacing the original representations and warranties with weakened terms like \"might\", \"should\", \"may\", \"arguably\", and \"potentially\", this change transforms what are supposed to be firm guarantees into uncertain possibilities. This makes it unclear whether Valeant is actually committed to these statements and significantly impacts the reliability of these assurances for Dova. The cumulative effect of these changes introduces doubt and undermines the enforceability of these provisions, weakening the protections Dova has under the agreement.",
                "location": "Section 10.2"
            }
        ]
    }
]